Form 4: ANAPTYSBIO CEO Faga Reports PSU Vesting, Tax-Related Stock Sales

ANAPTYSBIO's President and CEO, Daniel Faga, reported the vesting of performance-based restricted stock units and subsequent 'sell to cover' transactions to satisfy tax obligations.

Summary

• Daniel Faga, President, CEO, and Director of ANAPTYSBIO, INC. (ANAB), acquired 34,300 shares of Common Stock on March 25, 2026.
• These shares represent performance-based restricted stock units (PSUs) that were earned upon the achievement of specific performance criteria, as certified by the Compensation Committee of the Issuer's Board of Directors.
• On March 27, 2026, Faga sold a total of 17,679 shares of Common Stock across multiple transactions.
• These sales were non-discretionary 'sell to cover' transactions executed solely to satisfy tax withholding obligations in connection with the vesting and settlement of the PSUs.
• The shares were sold at weighted average prices ranging from $56.613 to $65.99 per share.
• Following these reported transactions, Daniel Faga directly beneficially owns 495,965 shares of ANAPTYSBIO Common Stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. The earning of PSUs indicates the achievement of performance criteria, and the subsequent sales are routine tax-related transactions, not a discretionary divestment, thus not signaling negative sentiment.

Positives

• Daniel Faga earned 34,300 performance-based restricted stock units (PSUs), indicating the achievement of certain performance criteria by the company as certified by the Compensation Committee.

Negatives

• No inherently negative discretionary transactions were reported; the sales were solely to cover tax withholding obligations and do not represent a discretionary divestment by the Reporting Person.

Future Outlook

NA

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of PSUs.
• The sale was to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions are a common and routine practice for executives receiving equity compensation, such as performance-based restricted stock units. These transactions are generally not indicative of a change in management's outlook on the company's prospects or a discretionary divestment of shares.

Comparison to Industry Standards

• The 'sell to cover' transactions reported are standard practice for executives to manage tax liabilities arising from equity compensation. This is a common mechanism across industries for executives receiving performance-based awards, similar to practices seen at companies like Pfizer (PFE) or Microsoft (MSFT) when executives vest restricted stock units, ensuring compliance with tax obligations without requiring personal funds.

Stakeholder Impact

• Shareholders: The earning of performance-based restricted stock units (PSUs) by the CEO could be viewed positively as it signifies the achievement of company performance targets. The subsequent 'sell to cover' transactions are routine and generally have minimal impact on shareholder sentiment or share price.

Key Dates

Recommendation

The filing reports a routine insider transaction where the CEO earned performance-based restricted stock units and subsequently sold a portion to cover tax obligations. This 'sell to cover' is a non-discretionary event and does not reflect a change in the executive's investment sentiment or the company's fundamentals, thus warranting a 'hold' recommendation based solely on this filing.

Keywords

ANAPTYSBIO, ANAB, Daniel Faga, Form 4, Insider Transaction, Stock Sale, PSU, Restricted Stock Units, Executive Compensation, Tax Withholding